EMEA-002970-PIP01-21
Key facts
| Active substance |
Tildacerfont
|
| Therapeutic area |
Endocrinology-Gynaecology-Fertility-Metabolism
|
| Decision number |
P/0036/2022
|
| PIP number |
EMEA-002970-PIP01-21
|
| Pharmaceutical form(s) |
|
| Condition(s) / indication(s) |
Treatment of congenital adrenal hyperplasia
|
| Route(s) of administration |
Oral use
|
| Contact for public enquiries |
Spruce Biosciences, Inc.
E-mail: info@scendea.com |
| Decision type |
P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)
|